- Home
-
Press releases
-
Media academy
- Lung Cancer
- Breast Cancer
- Ovarian Cancer
- Head & Neck Cancer
- Targeted Therapy
Boehringer Ingelheim
|
One of the most accurate global systems for staging breast cancer is known as TNM staging. This separately assesses the size of the tumour, the location of the nodes and any metastases. The result for each stage is put together to form an accurate picture of an individual’s tumour at the time of diagnosis. |
||
 |
Localised Stage | |
|
Tumour is no more than 2cm and cancer cells have not spread beyond the breast |
||
|
Localised stage is an early stage of invasive breast cancer. The tumour is no more than 2cm and cancer cells have not spread beyond the breast. 60% of patients are diagnosed at this stage, and the 5-year relative survival is 98.6%.1
|
||
 |
Regional Stage |
|
| Tumour grows to more than 5cm and the lymph nodes in the armpit are affected but the tumour has not spread further | ||
| Regional stage is when the tumour grows to more than 5cm and the lymph nodes in the armpit are affected but the timour has not spread further. 33% of patients are diagnosed at this stage, and the 5-year relative survival is 83.8%.1 | ||
|
|
Distant Stage | |
| The cancer has spread to other parts of the body such as the bones, liver or lung. This is known as advanced or metastatic breast cancer | ||
|
In the Distant stage, cancer has metastasised and spread to other parts of the body, such as the bones, liver or lung. 5% of patients are diagnosed at this stage, and the 5-year relative survival is 23.4%.1
If you want to find out more about breast cancer, please launch our full animated infographic.
|
||
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.
